The below mentioned biotech stocks have witnessed a substantial change in their stock price today (29 January 2019). Both the stocks have published price sensitive news today. Let’s take a closer look at these stocks:
Volpara Health Technologies Limited (ASX: VHT)
A medical technology company, Volpara Health Technologies Limited (ASX: VHT) has reported Cash receipts of NZ$1.9 million in Q3 FY19 which is 192% higher than Q3 FY18. At the end of Q3 FY 2019, the company had NZ$17.1 million in cash. During Q3 FY 2019, the company expenses increased due to the expansion of the sales team in the US and the engineering team in Wellington. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
During the quarter, the company added NZ$755k of ARR (Annual Recurring Revenue) and NZ$4.3 million of TCV (Total Contract Value). The company’s overall churn remains less than 1 percent of Annual Recurring Revenue. The company believes that it will reach at least 85% growth in ARR by the end of March 2019 and will cover at least 7% of US women being screened. During the quarter, the company gained new capital contracts in India, Hungary, Japan, and Brazil. During the quarter, the company successfully launched its new product, the Volpara®Live! ™ system. The Average price per woman (ARPU) in the US for base Volpara®Enterprise™ product remains around US$2.50 in FY19 which is around 50 percent than FY 2018. For the six months ended 30 September 2018, the company reported the Net loss after tax of NZ$ 5,119k with basic and diluted loss per share of NZ$0.03. In the past six months, the share price of VHT increased by 60 percent as on 25 January 2019. VHT’s shares traded at $1.125 (-9.274% intraday) with a market capitalization of circa $222.39 million as on 29 January 2019.
ImpediMed limited (ASX: IPD)
Global provider of medical technology, ImpediMed limited (ASX: IPD) today announced that its interim detailed results of the PREVENT trial are going to be presented during the scientific session of the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS) in Texas from 30 April to 5 May 2019. PREVENT trial was conducted to evaluate the impact of BIS on detecting, monitoring and treating cancer-related lymphoedema. Following the release of this news, the share price of IPD increased by 28.947 percent as on 29 January 2019.
The opportunity to highlight the results of the PREVENT trial at the prestigious ASBrS meeting demonstrates the company’s commitment to improving the quality of care for millions of cancer survivors suffering from lymphoedema worldwide.
Recently, the company received a multi-year national purchasing agreement for its SOZO® Digital Health Platform from Ascension Health Resources. The company’ Annual Recurring Revenue (ARR) for SOZO® contracts grown to $1.8 million as of 30 September 2018, which was 38% higher from $1.3 million as of 30 June 2018. For the September quarter, the company reported the revenue of Medical Revenue of $0.9 million. The Net operating cash outflow in the September quarter decreased by 21 percent to $4.5 million.
In the past six months, the share price of IPD decreased by 55.29 percent as on 25 January 2019. IPD’s shares traded at $0.245 with a market capitalization of ~$72.01 million as on 29 January 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.